Ting Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ting Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chaim Putterman
Albert Einstein College of Medicine, Bronx, New York, USA
1 shared publication - Chandra Mohan
Department of Biomedical Engineering, University of Houston, Houston, Texas, USA
1 shared publication - Cherie T. Ng
Equillium, La Jolla, California, USA
1 shared publication - Chi Chiu Mok
Tuen Mun Hospital
1 shared publication - Dalena Chu
Equillium, La Jolla, California, USA
1 shared publication - Evan Der
Department of Rheumatology, Albert Einstein College of Medicine, Bronx, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 4 January 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (1)
The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication of systemic lupus erythematosus (SLE). CD6 and its ligand, activated leukocyte cell adhesion molecule (ALCAM), are involved in T cell activation and trafficking. Previously, we showed that soluble ALCAM is increased in urine (uALCAM) of patients with LN, suggesting that this pathway contributes to disease. To investigate, uALCAM was examined in 1038 patients with SLE and LN from 5 ethnically diverse cohorts; CD6 and ALCAM expression was assessed in LN kidney cells; and disease contribution was tested via antibody blockade of CD6 in murine models of SLE and acute glomerulonephritis. Extended cohort analysis offered resounding validation of uALCAM as a biomarker that distinguishes active renal involvement in SLE, irrespective of ethnicity. ALCAM was expressed by renal structural cells whereas CD6 expression was exclusive to T cells, with elevated numbers of CD6+ and ALCAM+ cells in patients with LN. CD6 blockade in models of spontaneous lupus and immune-complex glomerulonephritis revealed significant decreases in immune cells, inflammatory markers, and disease measures. Our data demonstrate the contribution of the CD6/ALCAM pathway to LN and SLE, supporting its use as a disease biomarker and therapeutic target.
- 4 January 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (1)
Top Cited PapersOpen AccessThe CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication of systemic lupus erythematosus (SLE). CD6 and its ligand, activated leukocyte cell adhesion molecule (ALCAM), are involved in T cell activation and trafficking. Previously, we showed that soluble ALCAM is increased in urine (uALCAM) of patients with LN, suggesting that this pathway contributes to disease. To investigate, uALCAM was examined in 1038 patients with SLE and LN from 5 ethnically diverse cohorts; CD6 and ALCAM expression was assessed in LN kidney cells; and disease contribution was tested via antibody blockade of CD6 in murine models of SLE and acute glomerulonephritis. Extended cohort analysis offered resounding validation of uALCAM as a biomarker that distinguishes active renal involvement in SLE, irrespective of ethnicity. ALCAM was expressed by renal structural cells whereas CD6 expression was exclusive to T cells, with elevated numbers of CD6+ and ALCAM+ cells in patients with LN. CD6 blockade in models of spontaneous lupus and immune-complex glomerulonephritis revealed significant decreases in immune cells, inflammatory markers, and disease measures. Our data demonstrate the contribution of the CD6/ALCAM pathway to LN and SLE, supporting its use as a disease biomarker and therapeutic target.